Trial Profile
Phase III trial of intranasal dexmedetomidine in patients with acute postoperative pain.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 29 Oct 2015
Price :
$35
*
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- Sponsors Societal CDMO
- 26 Oct 2015 According to Recro Pharma media release, the company has decided not to continue with the clinical program for Dex-IN in post operative pain after feedback from FDA on the phase II efficacy and safety data. It intends to pursue a phase II program in peri-procedural pan instead.
- 26 Oct 2015 Status changed from planning to withdrawn prior to enrolment, based on the information in the Recro Pharma media release.
- 27 Mar 2015 New trial record